Skip to content

Sickle Cell Disease (Pediatrics)

Anemia Management

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (opens new window)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Source‎: Lancet Haematol. 2023 ;10(4):e261-71.

Indexed‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (opens new window)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (opens new window)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Source‎: Acta Haematol 1995;94(3):128-34.

Indexed‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (opens new window)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (opens new window)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Source‎: Haematologica 2006;91(8):1076-83.

Indexed‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (opens new window)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (opens new window)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Source‎: J Obstet Gynaecol 2007;27(1):82-3.

Indexed‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (opens new window)